| Comparison of nitric oxide synthase inhibitors, phospholipase A2 inhibitor and free radical scavengers as attenuators of opioid withdrawal syndrome. | |
| | |
MedLine Citation:
|
PMID: 17989510 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chronic morphine-induced withdrawal syndrome after morphine cessation remains a severe obstacle in the clinical treatment of morphine. Previous studies have shown that nitric oxide synthetase (NOS) inhibitors may have therapeutic potential in morphine withdrawal in humans. The mechanisms that underlie expression of morphine-induced withdrawal syndrome are, however, not yet fully understood. Therefore, this study was designed to determine the mechanism of the expression of morphine-induced withdrawal syndrome in mice. Morphine-dependent mice showed marked body weight loss and several withdrawal signs after naloxone challenge. Pretreatment with a NOS inhibitor, such as N-nitro-L-arginine methyl ester (L-NAME) or 7-nitroindazole, but not aminoguanidine, significantly attenuated the expression of morphine-induced withdrawal syndrome. Furthermore, mepacrine (a phospholipase A2 inhibitor) significantly attenuated the morphine-induced withdrawal syndrome in a manner that was different than that with a NOS inhibitor. These results suggest that nNOS and phospholipase A2, which might increase free radicals, play an important role in the expression of morphine-induced withdrawal syndrome. On the contrary, free radical scavengers (including fullerenes, ascorbate-2-phosphate, and DL-alpha-tocopheryl phosphate) attenuated the expression of the morphine-induced withdrawal syndrome. These results indicate that free radicals play an important role in the expression of physical dependence on morphine, and fullerenes could be a potential clinical tool in the relief of morphine withdrawal syndrome. |
| | |
Authors:
|
Tomohisa Mori; Shinobu Ito; Kenji Matsubayashi; Toshiko Sawaguchi |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Behavioural pharmacology Volume: 18 ISSN: 0955-8810 ISO Abbreviation: Behav Pharmacol Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-11-08 Completed Date: 2008-01-24 Revised Date: 2009-07-07 |
Medline Journal Info:
|
Nlm Unique ID: 9013016 Medline TA: Behav Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 725-9 Citation Subset: IM |
Affiliation:
|
Department of Legal Medicine, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Ascorbic Acid / analogs & derivatives, therapeutic use Enzyme Inhibitors / therapeutic use* Free Radical Scavengers / therapeutic use* Hydroxyl Radical Male Mice NG-Nitroarginine Methyl Ester / therapeutic use Naloxone / pharmacology Nitric Oxide Synthase / antagonists & inhibitors* Opioid-Related Disorders / drug therapy* Phospholipases A2 / antagonists & inhibitors* Substance Withdrawal Syndrome / drug therapy* Superoxides / metabolism alpha-Tocopherol / analogs & derivatives, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Free Radical Scavengers; 11062-77-4/Superoxides; 23313-12-4/ascorbate-2-phosphate; 3352-57-6/Hydroxyl Radical; 38976-17-9/alpha-tocopherol phosphate; 465-65-6/Naloxone; 50-81-7/Ascorbic Acid; 50903-99-6/NG-Nitroarginine Methyl Ester; 59-02-9/alpha-Tocopherol; EC 1.14.13.39/Nitric Oxide Synthase; EC 3.1.1.4/Phospholipases A2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and her...
Next Document: The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-select...